Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis.
Yanting ShihShile ChenJie HuangYongheng ChenZicong ZhuQian ZhaoXiaoqing ZhaoFeng XueJie XiangXiaosong ChenXuemei ZhuMeng PanJun WuJie ZhengHao LiHua CaoPublished in: Rheumatology (Oxford, England) (2023)
Increased galectin-9 levels were related to tumor progression in CRDM, and galectin-9 was downregulated upon cancer treatment. Monitoring serum galectin-9 levels and anti-TIF1-γ antibodies might be an attractive strategy to achieve tumour diagnosis and predict CRDM outcome.